Latest Medicinal Cannabis News

Page 1 of 6
LGP Cannatrek generated A$4.4 million in net operating cash flow on unaudited quarterly revenue of A$26.0 million, providing the first clean look at the merged group’s operations. Cost synergies, Danish production upgrades and UK expansion are advancing, while a pending TGA penalty remains an unresolved risk.
Ada Torres
Ada Torres
30 Oct 2026
Cann Group’s September quarter delivered a sharp increase in revenue and exports as its Mildura GMP facility gained traction in Europe. But with just $49,000 in cash, $626,000 of undrawn debt capacity and an estimated 0.9 quarters of funding, the recovery still depends on collections and further financing.
Ada Torres
Ada Torres
30 Oct 2026
Rua Bioscience has raised approximately NZ$1.0 million through its rights offer, well short of the NZ$2.8 million sought. The medicinal cannabis company says it still needs more working capital to fund inventory for its UK expansion.
Ada Torres
Ada Torres
20 Oct 2026
ECS Botanics has delivered a fifth consecutive quarter of positive operating cash flow, while branded sales and international expansion continue to reshape the business. The next test is whether planned UK and Polish launches can convert into recurring revenue.
Ada Torres
Ada Torres
19 Oct 2026
ECS Botanics is taking six Australian-grown medicinal cannabis flower products into the UK through Curaleaf Laboratories, with initial supply targeted for November. The two-year deal offers access to UK sell-through but no guaranteed volumes, revenue or minimum purchases.
Victor Sage
Victor Sage
7 Oct 2026
Cann Group’s FY2026 profit was transformed by a one-off A$55.7 million debt-forgiveness gain, while a leaner cost base and new export sales offered more durable progress. The company remains loss-making on a normalised basis and dependent on lender waivers and a future refinancing.
Victor Sage
Victor Sage
30 Sept 2026
Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.
Ada Torres
Ada Torres
22 Sept 2026
ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.
Ada Torres
Ada Torres
28 Aug 2026
Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.
Victor Sage
Victor Sage
28 Aug 2026
Rua Bioscience has gained regulatory approval in New Zealand for five new medicinal cannabis products, setting the stage for domestic sales and advancing its strategy to integrate local cannabis genetics.
Ada Torres
Ada Torres
4 Aug 2026
Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.
Ada Torres
Ada Torres
30 July 2026
ECS Botanics plans to introduce two 2g all-in-one vape products under its OzSun brand in mid-August 2026, expanding its higher-margin B2C portfolio with a capital-efficient supply model.
Ada Torres
Ada Torres
27 July 2026

Browse the archive

Full archive